US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR® (trospium chloride extended-release capsules) are invalid. Watson's Abbreviated New Drug Application for a generic version of Sanctura XR® is pending with the Food and Drug Administration. 

Sanctura XR® is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. For the twelve months ending April 30, 2012, Sanctura XR® had total U.S. sales of approximately $66 million, according to IMS Health data.